Skip to content

Author

T. Muranen

We have 2 of 152 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

A noncanonical function of the tyrosine degradation enzyme FAH drives CDK4/6 inhibitor resistance in breast cancer

Nuclear FAH was enriched in tumors from relapsed patients, and inhibition of CDK9 reversed FAH-mediated resistance and revealed CDK9 as a therapeutic vulnerability in CDK4/6 inhibitor–resistant HR+ breast cancer.

Jenny M. Hogstrom, Hanna M. Doh, A. Kump et al. · 0 citations
Open access Jul 2026

Multi-modal data integration reveals functionally credible predictive biomarkers in ovarian cancer.

An integrated whole-genome and transcriptome workflow is developed to systematically distinguish functionally credible, predictive driver aberrations from non-functional alterations across all classes of genomic events in ovarian high-grade serous carcinoma.

T. Muranen, A. Hainari, D. Afenteva et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.